References
Gehling UM, Ergün S. Mechanisms of tumour vascularisation. memo, 1(1): 3–7, 2008
Grossi F, Brianti A, Defferari C, Pronzato P. Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. memo, 1(1): 13–16, 2008
Ribatti D, Vacca A. Angiogenesis and anti-angiogenesis in haematological diseases. memo, 1(1): 31–33, 2008
Dediu M. Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how? memo, 1(2): 61–65, 2008
Kornek G, Scheithauer W, Anghel R, Bodoky G, Ciardiello F, Ciuleanu T, Glynne-Jones R, Gruenberger T, Koza I, Ocvirk J, Petruzelka L, Poston G, Ramadori G, Schmiegel W, Segaert S, Tabernero J, Zwierzina H, Zielinski C. Consensus on the medical treatment of colon cancer. memo, 1(2): 79–90, 2008
Gastl G. Approaching personalized cancer medicine. memo, 1(3): 121–124, 2008
Loeffler-Ragg J, Sarg B, Mueller D, Auer T, Lindner H, Zwierzina H. Proteomics, a new tool to monitor cancer therapy? memo, 1(3): 129–136, 2008
Kandioler D. Personalized medicine – p53 gene analysis for the prediction of response to neoadjuvant therapy in esophageal cancer. memo, 1(3): 137–142, 2008
Gabriel M, Andergassen U, Virgolini IJ. Individualized molecular cancer therapy based on radiolabelled somatostatin analogues. memo, 1(3): 171–176, 2008
Wolf D. Current status of immunotherapy for cancer treatment. memo, 1(4): 191–193, 2008 (this issue)
Zielinski CC. Treatment of metastatic breast cancer: an historical perspective. memo, 1(4): 229–236, 2008 (this issue)
Zach O, Zellhofer B, Födermayr M, et al. The detection of circulating tumor cells in blood of metastatic breast cancer patients is of prognostic relevance. memo, 1(4): 285–289, 2008 (this issue)
Rights and permissions
About this article
Cite this article
Hilbe, W. The first year of Memo – Reporting oncological progress in Europe. memo 1, 187–188 (2008). https://doi.org/10.1007/s12254-008-0060-z
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0060-z